IPO Price Range: ₹70 - 74
Min Investment
₹14,800
IPO Size
₹2,200 Cr
IPO Status
Quantity in 1 Lot
200
Max Bid allowed
13
Listing Exchange
NSE
IPO subscribed over
🚀 1.8x
This IPO has been subscribed by 2.73x in retail and 2.06x in QIB.
Total Subscription | 1.8x |
Retail Individual Investors | 2.73x |
Qualified Institutional Buyers | 2.06x |
Non Institutional Investors | 0.68x |
Bid Opening Date | 7 Nov 2024 |
Bid Closing Date | 11 Nov 2024 |
Allotment Date | 12 Nov 2024 |
Issue Size | ₹2,200Cr |
Quantity in 1 lot | 200 |
Granular retail health insurer with a focus on delivering robust GWP growth, capital efficiency and profitability.
Our diverse product suite for customers, bolstered by our track record for product innovation.
Technology-led automated approach to customer servicing.
Bupa parentage and brand associated with health insurance and healthcare.
Our domain knowledge and experience in claims and provider management.
Multi-channel diversified pan-India distribution, with technology-led empowerment of distribution partners.
Our technology and analytics platforms.
Experienced management team backed by established investors and underpinned by sustainable employment practices.
Its profitability depends on its ability to manage the company underwriting risks and appropriately price its products and any failures to accurately estimate medical expenses or the frequency of claims could have a material adverse effect on its business, financial condition, results of operations, cash flows and prospects.
As a significant portion of its business is generated from the health insurance line of business, any adverse changes to the demand for health insurance products and the retail health insurance sector may affect the sale of its health insurance products and in turn its business and profitability.
If the company fails to align its products, including in particular, its retail health insurance products with the needs of the company targeted customer demographics or if its unsuccessful in its product development strategy, the companys business could be materially and adversely affected.
The company is subject to extensive supervision and regulatory inspections (onsite and offsite, thematic or otherwise) by IRDAI and any regulatory and statutory actions against it or the company distributors could cause it reputational harm and have a material adverse effect on its business, financial condition, cash flows, results of operations and prospects.
The success of its business depends on the company ability to attract and retain, as well as obtaining timely approvals from IRDAI with respect to, its senior management and employees in critical roles, and the loss of their services could have a material adverse effect on its business, financial condition, results of operations, cash flows and prospects.
The company is dependent on its intermediated distribution channels, particularly individual agents, corporate agents and brokers, and if the company is unable to develop and grow its network of distributors or attract, retain and incentivize its distributors, it could have a material adverse effect on the companys business, financial condition, results of operations, cash flows and prospects.
The company has incurred losses in Fiscal 2022 and the three months ended June 30, 2024 and June 30, 2023 and may not be able to maintain its profitability in the future, which could adversely affect its operations and financial condition and the trading price of the company Equity Shares.
The company failures to accurately and timely pay claims could lead to customer dissatisfaction and result in regulatory actions or penalties, which could materially and adversely affect its business, financial condition, results of operations, cash flows and prospects.
The company may be unable to obtain reinsurance on a timely basis at reasonable costs and could be exposed to credit risks in its reinsurance contracts, including with General Insurance Corporation of India (GIC Re).
Its Directors and Promoters may enter into ventures which are in businesses similar to its.
Investors | Holdings % |
Bupa Singapore Holdings Pte.Lt | 62.19% |
Bupa Investment Overseas Ltd | 0% |
Fettle Tone LLP | 26.8% |
Organisation | Niva Bupa Health Insurance Company Ltd |
Headquarters | New Delhi |
Industry | Insurance |